BI-770371

N/A

Report date: 2026/03/23 20:03:44
First In Class

Base Information

Drug NameBI-770371
Drug Alias NameBI-770371
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionT lymphocytes stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCheckpoint kinase inhibitors +[4] 
TargetsCheckpoint kinaseSignal-regulatory protein alpha
Therapy Area/IndicationsSolid tumoursLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOse Immunotherapeutics
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Inactive CompaniesN/A
Active IndicationsSolid tumoursLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A